Efficacy and Tolerability after Unusually Low Doses of Dasatinib in Chronic Myeloid Leukemia Patients Intolerant to Standard-Dose Dasatinib Therapy

We report our experience in 4 patients with chronic myeloid leukemia (CML) who had discontinued imatinib as a result of adverse events and had switched to dasatinib. The chronic phase (n 2) and accelerated phase (n 2) CML patients received dasatinib at starting dose of 100 and 140 mg once daily, res...

Descripción completa

Detalles Bibliográficos
Autores principales: Serpa, Mariana, Sanabani, Sabri S., Bendit, Israel, Seguro, Fernanda, Xavier, Flávia, Barroso, Cláudia Bitti, Conchon, Monika, Dorlhiac-Llacer, Pedro Enrique
Formato: Texto
Lenguaje:English
Publicado: Libertas Academica 2010
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3018898/
https://www.ncbi.nlm.nih.gov/pubmed/21234296
http://dx.doi.org/10.4137/CMO.S6413

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3018898/
https://www.ncbi.nlm.nih.gov/pubmed/21234296
http://dx.doi.org/10.4137/CMO.S6413

Ejemplares similares